



Thursday 30 January 2025

- 09.30 - 10.15 **Registration and welcome with coffee/tea**
- 10.15 - 10.25 **Opening by the chair of the NVED**
- 10.25 - 11.30 **Session I - Human skin models for novel applications**
 Session chairs: Ellen van den Bogaard (*Radboudumc*) and Jasper Koning (*AmsterdamUMC*)
1. Britt van der Leeden *AmsterdamUMC* Development and characterization of a reconstructed human skin burn wound model.
 2. Jolienne Wichers Schreur *LUMC* Development of human skin equivalents representing cutaneous T-cell lymphoma.
 3. Luca Meesters *Radboudumc* iPSC-derived keratinocyte models for in vitro atopic dermatitis research.
 4. Kim Schilders *ADBC* Generation of full skin constructs from hair follicle stem cells.
 5. Jonas Jäger *AmsterdamUMC* Towards next generation reconstructed human skin: monocyte perfusion of a vascularized dermis in a multi-organ-chip.
- 11.30 - 12.10 **Guest lecture by dr. Raymond Staals (*WUR*): "CRISPR-Cas, from a bacterial defense system to a powerful genetic tool in humans"**
- 12.10 - 13:10 **Lunch**
- 13.10 - 14.15 **Session II - Immunology**
 Session chairs: Ferenc Scheeren (*LUMC*) and Rosalie Luiten (*AmsterdamUMC*)
6. Fenna de Bie *LUMC* Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment.
 7. Ahmed Elfiky *UMCU* Impact of dupilumab and upadacitinib treatment on epigenetic and transcriptomic alterations in skin-homing T cells of atopic dermatitis patients.
 8. Emma Holtappels *AmsterdamUMC* Identifying biological processes involved in clinical response to treatment in the autoimmune disease vitiligo using proteomics.
 9. Nicoline van Buchem *AmsterdamUMC* The potential role of trained immunity in the pathogenesis of autoimmune vitiligo.
 10. Alex Rooker *AmsterdamUMC* Vitiligo-associated bystander lysis in basal cell carcinoma.
- 14.15 - 15.45 **Poster presentations session I with coffee and tea; selection for poster walks by jury**
 14:15 - 15:00 → odd poster numbers presenting at poster
 15:00 - 15:45 → even poster numbers presenting at poster
- P1. Juliette Kersten (*LUMC*) Modified recommendations for the radiation dose in patients with cutaneous T-cell lymphoma and localised lesional disease: a retrospective analysis of treatment outcomes.
 - P2. Malak Al-Gawahiri (*Radboudumc*) The importance of psychological and socioeconomic risk factors for depression and anxiety among Dutch patients with mild-to-severe psoriasis: a web-based survey study.
 - P3. Digna de Bruin (*CHDR*) Imaging and immune-response profiling after UV-B provocation in healthy volunteers for proof-of-mechanism clinical trials.
 - P4. Rosanne Ottevanger (*LUMC*) Exploring the association of primary cutaneous CD30+ lymphoproliferative disorders and Inflammatory Bowel Disease in a Dutch cohort.
 - P5. Lisa van der Rijst (*UMCU*) Treatment goals and preferences of pediatric atopic dermatitis patients, young adults, and caregivers.
 - P6. Lisa van der Rijst (*UMCU*) Dupilumab-associated ocular surface disease in pediatric atopic dermatitis patients: results from the BioDay registry.
 - P7. H. Ibrahim Korkmaz (*AmsterdamUMC*) The post-burn immune response in burn patients: a pivotal role for complement.
 - P8. Leon Miltner (*UMCG*) Multimorbidity in adults with atopic dermatitis in a population-based cohort.
 - P9. Liana Barenbrug (*Radboudumc*) Incorporating the patients' voice in healthcare practice and informa-

tion provision regarding family planning and pregnancy: a questionnaire study among Dutch patients with psoriasis.

- P10. Florentine de Boer (*AmsterdamUMC*) Effect of repeated low dose UVR exposure on the skin inflammation threshold, skin biomarkers and vitamin D in healthy adults.
- P11. Andrew Morrison (*AmsterdamUMC*) Lymphatic endothelial cells enhance the physiology of a perfused vascularised lymph node-on-chip for studying skin-immune responses.
- P12. Noor van Hout (*Radboudumc*) Engineered live biotherapeutic products and their effects on UV light-irradiated keratinocytes.
- P13. Linda Godding (*Radboudumc*) Searching for relevant biomarkers in dermatological care: a survey among Dutch patients and dermatological care providers.
- P14. Juliette Simons (*UMCU*) Diagnostic management and monitoring of cholinergic urticaria patients in daily practice.
- P15. Shidi Wu (*LUMC*) Tumor-stroma interaction facilitates cutaneous T Cell Lymphoma cell proliferation and dynamic phenotype change in cancer-associated fibroblasts.
- P16. Lian van der Gang (*UMCU*) Early efficacy of dupilumab in atopic dermatitis: patient-reported outcomes versus objective sleep and scratching measures.
- P17. Lian van der Gang (*UMCU*) Daily practice experience of dupilumab treatment in patients with prurigo nodularis: a 28-week evaluation of clinical effectiveness and safety from the BioDay registry.
- P18. Nienke Veldhuis (*UMCU*) Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis.
- P19. Thijs van der Mark (*GGD Amsterdam*) Development and validation of blunt trauma in a reconstructed human skin model.
- P20. Reineke Soegiharto (*UMCU*) Side effects of omalizumab in patients with chronic urticaria: a long-term multi-centre real-world study.
- P21. Reineke Soegiharto (*UMCU*) Exploring the disease duration of urticaria and associated clinical characteristics in Dutch primary care.
- P22. Nikita Koster (*CHDR*) A prospective, multi-center, observational biomarker real-world evidence study for in-depth profiling of patients with chronic immune-mediated inflammatory skin diseases in daily practice.
- P23. Rindert Venema (*UMCG*) Isolation and generation of a monoclonal human anti-desmoglein 3 antibody.
- P24. Margot Starrenburg (*ErasmusMC*) Dupilumab treatment decreases MBC2s, correlating with reduced Ige levels in pediatric atopic dermatitis.
- P25. Marjolein Brands (*UMCG*) The validity and reliability of patient-provided photographs for the diagnosis and severity of hand eczema – preliminary results.
- P26. Roland Valentin Bumbuc (*AmsterdamUMC*) The acute phase response to burn injury: an in-silico modeling approach.
- P27. Tristan Bruijn (*NKI*) A systematic review of changes in melanocytic naevi during immune checkpoint inhibition and targeted therapy.
- P28. Birte Hell (*UMCU*) In vitro skin models for sensitization in food allergy.
- P29. Emily Kallen (*UMCU*) Almond allergy in adults: low discriminative ability for both almond sIgE and SPT.
- P30. Fauve van Veen (*MUMC+*) Exploring experiences and considerations in reproductive decision-making for patients with genodermatoses: a qualitative interview study.
- P31. Jaimy Klijnhout (*Radboudumc*) Staphylococcus aureus strain-specific host defense responses in keratinocytes.
- P32. Fauve van den Berge (*ErasmusMC*) SKINERGY CINDU: An exploratory multi-centre, two-part study to deep-phenotype chronic inducible urticaria and explore biomarkers for omalizumab response using a multimodal profiling approach.
- P33. Mengyao Zhou (*VU Amsterdam*) Polarization second harmonic generation imaging of collagen fiber organization in human healthy and scarred skin.
- P34. Nikki Henckens (*Radboudumc*) Patients' and clinicians' perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study.
- P35. Marie Chevalier (*LUMC*) Tumour micro-environment in chlormethine responders and non-responders in an early-stage mycosis fungoides cohort, using imaging mass cytometry.
- P36. Marjolein Hiel (*UMCG*) Navigating the challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey.
- P37. Zixian Liang (*UMCG*) Diagnostic value of complement fixation test in routine diagnostics of pemphigoid diseases: one year of prospective analysis.

- P38. Cisse Vermeer (*UMCG*) Safety of antisense oligonucleotide therapy: A systematic review and meta-analysis on adverse events in clinical studies.
- P39. Fieke Rosenberg (*UMCG*) A genome-wide association study of contact allergy to p-phenylenediamine.

15.45 – 16.50

Session III - Biomarkers and genetics

Session chairs: Dirk-Jan Hijnen (*Radboudumc*) and Antoni Gostynski (*MUMC+*)

- | | |
|--------------------------------------|--|
| 11. Alesha Louis <i>LUMC</i> | The human skin microbiome and physical barrier integrity in aging. |
| 12. Sara Marchisio <i>LUMC</i> | Evaluation of CD39, CD73, and CD38 as potential biomarkers for monitoring Mogamulizumab response in Sézary Syndrome. |
| 13. Eddy de Boer <i>UMCG</i> | Long-read sequencing cracks unsolved cases in Epidermolysis Bullosa. |
| 14. Merve Hatun Erkeyman <i>UMCG</i> | IgA is related to a more severe mucous membrane pemphigoid. |
| 15. Marie-Eline Debeuf <i>MUMC+</i> | Exploring the therapeutic effect of Er:YAG laser on Hailey-Hailey disease through transcriptomics. |

16:55 - 17:25

Marcel Jonkman lecture by dr. Marieke Bolling (*UMCG*): "Opportunities and challenges in the past and future in the field of genodermatoses"

17.30 - 19.45

Drinks and Dinner

19.45 - 20.30

25th general assembly of the NVED

20.30 - 01.00

PubQuiz and Dancing

Friday 31 January 2025

09.00 - 10.05

Session IV – Treatment of atopic dermatitis

Session chairs: Martijn van Doorn (*ErasmusMC*) and Robert Rissmann (*CHDR*)

- | | |
|--|--|
| 16. Lisa van der Rijst <i>UMCU</i> | Impact of dupilumab on immune-related proteins in skin tape strips and serum of pediatric atopic dermatitis patients. |
| 17. Florence Vroman <i>UMCU</i> | The effect of dupilumab on the microbiome of lesional skin, facial skin and nose in moderate to severe AD patients treated in daily practice: data from the BioDay registry. |
| 18. Aranka Gerritsen <i>Radboudumc</i> | Restoring interleukin(IL)-22 induced severe atopic dermatitis (AD) hallmarks in vitro by dual targeting of epidermal defects and inflammation. |
| 19. Margot Starrenburg <i>UMCU</i> | Impact of tralokinumab on skin-homing T cells and IL-4 and IL-13 receptor dynamics in patients with atopic dermatitis. |
| 20. Nienke Veldhuis <i>UMCU</i> | Long-term ophthalmological follow-up of atopic dermatitis patients treated with dupilumab. |

10.05 - 11.10

Poster presentations (selected for poster prize) with coffee and tea

11.10 - 12.15

Session V – Innovations in dermatology

Session chairs: Remco van Doorn (*LUMC*) and Marcel Bekkenk (*AmsterdamUMC*)

- | | |
|--|--|
| 21. Wouter Ouwerkerk <i>AmsterdamUMC</i> | Cancer-immunogram analyses to predict the heterogeneous clinical response to immunotherapy in metastatic melanoma patients. |
| 22. Myrthe Moermans <i>MUMC+</i> | Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: long-term results of a multicenter randomized controlled trial. |

	23. Elise Beljaards <i>LUMC</i>	Association of skin barrier function, bacterial colonization, and inflammation with disease activity in mycosis fungoides and Sézary syndrome.
	24. Veerle Merkus <i>LUMC</i>	Tumor microenvironment of metastasized and non-metastasized cutaneous squamous cell carcinoma in organ transplant patients.
	25. Inger Kreuger <i>LUMC</i>	Spatial gene expression and micro-environmental changes during nevus to melanoma transition.
12.15 - 13.15	Lunch	
13.15 - 13.55	Guest Lecture by Prof. dr. Barbara Horvath (UMCG): “Autoimmune blistering diseases; Bridging basic research and clinical outcomes”	
13.55 - 14.47	Session VI – Inflammatory skin disease and biologics	
	Session chairs: Marjolein De Bruin-Weller (<i>UMCU</i>) and Heike Röckmann (<i>UMCU</i>)	
	26. Catherine Mergen <i>LACDR</i>	Stratum corneum ceramide alterations and barrier dysfunction in psoriasis normalize with guselkumab treatment.
	27. Linda Godding <i>Radboudumc</i>	Real-world cost-per-responder among the different classes of biologics for psoriasis.
	28. Marjolein Hiel <i>UMCG</i>	Phenotype transition in relapsed pemphigus patients after rituximab therapy: a retrospective single-center analysis.
	29. Juliette Simons <i>UMCU</i>	Effectiveness of ciclosporin in omalizumab-refractory chronic urticaria patients.
14.47 - 15.10	Awards for best presentation and poster	
15.10	Closure	

Meeting Location:

Congress hotel ‘De Werelt’
Westhofflaan 2
6741 KH Lunteren
Tel: 0318-484641

Accreditation:

The NVDV has awarded 11 points for full participation in this scientific meeting last year; accreditation for 2025 is applied for.

Program committee:

Michel van Geel (*MUMC+*), Ellen van den Bogaard (*Radboudumc*), Gilles Diercks (*UMCG*), Luba Pardo (*ErasmusMC*), Walbert Bakker (*AmsterdamUMC*), Abdoel El-Ghalbzouri (*LUMC*), Daphne Bakker (*UMCU*), Ibrahim Korkmaz (*AmsterdamUMC*)

Jury for presentation prize:

Hanna Niehues (*Radboudumc*), Joost Meyer (*UMCG*), Tom Wolswijk (*MUMC+*)

Jury for poster prize:

Emma Holtappels (*AmsterdamUMC*), Gilles Diercks (*UMCG*), Ferenc Scheeren (*LUMC*)

NVED board:

Remco van Doorn (president and representative in NVDV ‘Commissie Nascholing’, *LUMC*), Antoni Gostynski (*MUMC+*), Rosalie Luiten (secretary, *AmsterdamUMC*), Jeroen Bremer (treasurer, *UMCG*), Patrick Zeeuwen (coordination abstracts and program, *Radboudumc*)